Increased respiratory drive relates to severity of dyspnea in systemic sclerosis

Maarten K Ninaber1*, Willem BGJ Hamersma1, Annemie JM Schuerwegh2 and Jan Stolk1

Abstract

Background: Dyspnea may be a presenting symptom in progressive systemic sclerosis (SSc). Respiratory drive (mouth occlusion pressure, MOP, at rest and during CO2 rebreathing, 7% CO2, 93% O2) is a major determinant of dyspnea and may relate to the magnitude of dyspnea.

Methods: In a prospective design, MOP at 0.1 sec (P0.1) was measured in 73 SSc patients while breathing room air and during CO2 rebreathing. An abnormal VE/P0.1 is defined as < 8 L/min/cm H2O. Dyspnea scores were assessed by a shortness of breath questionnaire (UCSD dyspnea scale).

Results: Mean P0.1 in patients with normal VE/P0.1 (n = 45) was 1.1 ± 0.04 and 1.6 ± 0.08 cm H2O in patients with abnormal VE/P0.1 (n = 28), p <0.001. ΔP0.1/ΔPetCO2 differed significantly between these groups (0.45 versus 0.75 cm H2O/mmHg, P < 0.001), but no significant difference was present in ΔVE/ΔPetCO2. VE/P0.1 showed the highest significant correlation with the UCSD dyspnea score (r = −0.76, p <0.001). UCSD cut-off value for abnormal VE/P0.1 was 8.5 (sensitivity 93%, specificity 96%, area under the curve 0.98).

Conclusions: In SSc patients an abnormal VE/P0.1 better relates to the severity of dyspnea than traditional lung function parameters and can easily be assessed at first outpatient consultation.

Keywords: Respiratory drive, Systemic sclerosis, Dyspnea evaluation

Background

Systemic sclerosis (SSc) is a rare, heterogeneous condition of unknown etiology characterized by microvascular injury and deposition of excess collagen in skin and internal organs [1]. Principle subsets of SSc include limited cutaneous SSc (lcSSc) and diffuse cutaneous SSc (dcSSc) [2]. Importantly, progressive systemic sclerosis may involve interstitial lung disease (ILD) resulting into a restrictive lung function pattern abnormality [1]. In addition, pulmonary arterial hypertension (PAH) may arise in the course of the disease [1]. Validated measures to monitor progression of SSc are necessary for clinical trials and routine care of patients with SSc. Dyspnea as a presenting symptom occurs in 20% of newly diagnosed SSc patients and 70% of patients with SSc complicated by ILD or PAH complain of dyspnea [1]. Importantly, early recognition of disease progression related to organ damage and initiation of treatment may improve health-related outcomes. Lung volumes and gas transfer studies are related to disease severity in SSc [1] and used for initiation of treatment and evaluation. However, whether the magnitude of dyspnea relates to these pulmonary function tests is not known.

The impedance of the respiratory system is influenced by lung and chest wall compliance and respiratory flow resistance [3]. An increased respiratory impedance is recognized as the most frequent cause of dyspnea [3]. Other respiratory abnormalities resulting into dyspnea may include hypoxia, respiratory muscle weakness or pulmonary vasculopathy (pulmonary embolisms, pulmonary arterial hypertension). In progressive SSc, dyspnea may arise from an increased impedance of the respiratory system caused by ILD. In SSc, ILD or limited chest wall excursions due to a thickened thoracic skin is considered to cause this increased impedance [4,5]. Furthermore, dyspnea may result from an inappropriate ventilatory response upon the chemoreflex drive at rest and to hypercapnia [6,7].

To assess the ventilatory output as an index of the respiratory drive, resting ventilation (VE) and tidal volumes...
can be evaluated [8]. Ventilation, however, is an imperfect output parameter of the respiratory drive since it is affected by alterations in the impedance of the respiratory system (i.e. mechanical properties of the lung and chest wall) independently of changes in respiratory sensitivity to hypercapnia [3,6,9]. To assess the respiratory drive, mouth occlusion pressures (MOP) as an index of the output can be measured [3]. Important advantages of this technique include the reproducibility within each subject and reported values independent of age [10]. In a study of normal subjects and patients with ILD, a V'E/P0.1 greater than 8 l/min/cm H2O sharply separated a normal from an abnormal response [10]. Therefore, in patients who report dyspnea and who have concomitant ILD, a low V'E to a high P0.1 (i.e. low V'E/P0.1) is expected.

In addition to V'E/P0.1 at rest, the respiratory drive to hypercapnia (P0.1 to CO2, i.e. ΔP0.1/ΔPetCO2) provides insight into the central chemoreflex drive to hypercapnia [11-13]. In patients with ILD and dyspnea, the central chemoreflex drive may result into a falsely low ventilatory response to hypercapnic stimulation [7]. To overcome this, the central chemoreflex drive to hypercapnia may be assessed by mouth occlusion pressures (ΔP0.1/ΔPetCO2) [6,11,12].

Based on the above we hypothesized that in patients with SSc the respiratory drive, as measured by P0.1, V'E/P0.1 and mouth occlusion pressures to CO2 rebreathing, may better relate to the magnitude of reported dyspnea than the severity of gas transfer or lung volume impairment as measured by PFTs. Furthermore, we hypothesized that the respiratory drive to hypercapnia is increased in SSc patients who reported dyspnea.

### Methods

#### Patients

We prospectively screened SSc patients referred to an outpatient targeted health care program. All patients underwent an intensive screening procedure which included PFTs, serum laboratory testing, echocardiography, high-resolution chest CT scanning (HRCT) and a cardiopulmonary exercise test (CPET). Furthermore, all patients consulted a rheumatologist, cardiologist and a pulmonologist. All tests were done in one or two consecutive days. Patients were classified as limited systemic sclerosis (lcSSc) or diffuse systemic sclerosis (dcSSc) according to the LeRoy criteria [2].

#### Ethics

The local Medical Ethical Committee of the Leiden University Medical Center approved the protocol. A written informed consent was obtained from each patient prior to enrollment.

### Standard pulmonary function testing

PFTs were measured in all SSc patients including spirometry and gas transfer studies and expressed as percentage predicted [14,15]. Total lung capacity (TLC) was measured by the multiple breath helium dilution method [14] and diffusion capacity for carbon monoxide (DLCO) by the single breath carbon monoxide method [15].

#### Measuring mouth occlusion pressures during resting ventilation and CO2 rebreathing

Subjects were seated comfortably, attached to the mouthpiece with a noseclip in place. At randomized intervals, and without the subject’s knowledge, the inspiratory side of the rebreathing circuit was occluded during late expiration. The pressure generated at 0.1 s after the onset of inspiration was obtained in each subject during several minutes with a minimum of 10 measurements prior to the rebreathing test [3]. Thereafter, occlusion pressures were measured simultaneously during CO2 rebreathing at randomized intervals [3,16]. The slope of this curve was used as an index of the respiratory drive to hypercapnia (i.e. central chemoreflex drive) and reported as ΔP0.1/ΔPetCO2 [3,16].

#### Measuring the hyperoxic ventilatory response to hypercapnia (HCVR)

We used a simple rebreathing technique according to Read’s rebreathing technique, which consisted of a rebreathing bag filled with a gas mixture (7% CO2 and 93% O2) [17]. In the rebreathing bag, a total volume of approximately twice the measured vital capacity of the patient was used.

Under hyperoxia the ventilatory response to hypercapnia (HCVR) represents the central chemoreflex response only, assuming that the peripheral chemoreflex drive is suppressed by hyperoxia [16,17]. Equilibrium of pressures between CO2 in cerebral blood and end-tidal PCO2 exhalation at the mouth (PetCO2) is expected not to occur before recirculation of cerebral blood flow [17]. Respiratory volumes were recorded by a turbine volume measuring device (Oxycon-Pro, Jaeger). The Oxycon Pro was calibrated according to the instruction manual before each test (Oxycon instruction manual ver. 4.5. Erich Jaeger GmbH, Hoechberg, Germany) [18]. Oxygen and CO2 analyzers were calibrated with room air and certified calibration gases at 180 kPa (16% O2, 5% CO2 and 79% N2). The flow turbine (Triple V, Erich Jaeger GmbH, Hoechberg, Germany) was calibrated with a 3.00 liter 5520 series calibration syringe (Hans Rudolph, Inc, Kansas City, USA). Both gas and volume calibration were repeated until the difference between consecutive calibrations was less than 1%. Therefore, measurements were not considered to be influenced under hyperoxia. Expired gas at the mouth was sampled continuously.
and analyzed for PetCO2 by a fast-response infrared analyzer. The software calculated tidal volumes, inspiratory and expiratory times, minute ventilation, and PetCO2 on a breath-by-breath basis. The hyperoxic ventilatory response to hypercapnia (HCVR) was measured during several minutes after equilibrium between the end-tidal CO2 and mixed venous CO2. In this phase, a linear increase in V E with respect to PetCO2 was observed. The slope of this curve was used as the index of the ventilatory central chemosensitivity and reported as ΔV E/ΔPetCO2 [17].

UCSD shortness of breath questionnaire
We used a previously validated shortness of breath questionnaire which evaluates in 24-items self-reported shortness of breath while performing a variety of activities of daily living [19]. It was administered by MKN prior to the MOP and rebreathing study while the subject sitting comfortably.

Statistical analysis
Statistical analysis was performed with the SPSS 20.0 package (SPSS, Inc., Chicago, IL, USA). Continuous variables are expressed as mean value ± standard deviations. P values < 0.05 were considered significant. Categorical data are presented as frequencies and percentages. Statistical comparisons were performed by using Student’s T-test for continuous variables, and chi square test for binary variables. Correlations between clinical parameters, pulmonary function tests, were expressed in terms of Pearson’s or Spearman’s correlation coefficient when appropriate. The receiver operating characteristic (ROC) curve was used to evaluate the optimal cut-off value for the UCSD dyspnea score in relation to an abnormal V E/P0.1.

Results
In total, 73 SSc patients were prospectively evaluated by measuring PFTs, MOP and the hyperoxic ventilatory response to hypercapnia (HCVR). Patients were classified by their V E/P0.1 according to Scott GC and Burki NK [10], where ≥ 8 L/min/cmH2O was defined as normal.

Anthropometric and lung function data are presented in Table 1. In the group with a V E/P0.1 ≥ 8 L/min/cmH2O, lcSSc patients were significantly more present. In all patients with an abnormal V E/P0.1 (< 8 L/min/cmH2O), spirometric and gas transfer studies were significantly lower. All SSc patients were normocapnic at rest (PaCO2 = 5.24 ± 0.41 kPa).

Indices of MOP differed significantly between the two groups (Table 2). In contrast, there was no difference in the hyperoxic ventilatory response to hypercapnia. In our study, patients with a normal V E/P0.1 had a mean ΔP0.1/ΔPetCO2 of 0.45 ± 0.19 cmH2O/mmHg, which differed significantly from patients with an abnormal V E/P0.1. The latter group had an increased respiratory drive to hypercapnia (mean ΔP0.1/ΔPetCO2 0.75 ± 0.42 cmH2O/mmHg).

All pulmonary function test parameters correlated inversely and significantly with the UCSD shortness of breath questionnaire (coefficient of correlation ranging from −0.39 to −0.49). V E/P0.1, however, showed the highest significant correlation with the UCSD dyspnea score (r = −0.76, p < 0.001, Figure 1). The cut-off value in UCSD dyspnea score for an abnormal V E/P0.1 was 8.5 (sensitivity 93%, specificity 96%, area under the curve 0.98).

Discussion
We report that in SSc patients with an abnormal inspiratory respiratory drive (V E/P0.1 < 8 L/min/cmH2O) the sensation of dyspnea as measured by the UCSD dyspnea score differed from SSc patients with a normal respiratory drive. In addition, with a cut-off value of 8.5, the dyspnea score showed a high sensitivity and specificity for an abnormal V E/P0.1. Furthermore, an abnormal V E/P0.1 better relates to the magnitude of dyspnea than traditional lung function parameters and in these SSc patients an increased central chemoreflex drive to CO2 is present. Therefore, at first outpatient consultation, SSc patients complaining of dyspnea can easily be classified by using mouth occlusion pressures.

We showed that the level of dyspnea perception measured by the UCSD shortness of breath questionnaire [19] had a strong inverse correlation with the inspiratory neuromuscular drive as measured by V E/P0.1 (Figure 1). A high dyspnea score and an increased respiratory drive to hypercapnia suggest that the work of breathing is increased due to an increased respiratory impedance [7,10]. An increased activation of central respiratory centers results not only into an increase in minute ventilation but also into an increased perception of dyspnea [20]. The basis for this awareness originates from the exchange in information between the motor and sensory cortex and is referred to as corollary discharge [20]. Although the work of breathing is not the sole cause of dyspnea, increased effort as a result from an increased mechanical load causes a heightened sense of respiratory effort. Consequently, this may explain the strong correlation between the dyspnea score and the respiratory drive in the present study. This drive can be easily measured using mouth occlusion pressures at rest. As our results indicate, it better relates to dyspnea than impairment in lung volumes or gas transfer and may be present before significant impairment in these function tests arises. Therefore, measurement of the neuromuscular inspiratory drive may function in clinical practice in SSc patients complaining of dyspnea as a screening tool for detection of ILD or PAH.

Ventilation and its components, tidal volume and breathing frequency, depend on the compliance of the respiratory system and airway resistance [3,9-11]. Importantly,
one would like to differentiate patients who will not breathe because of central or neuromuscular inadequacy from those who cannot breathe because of mechanical abnormalities of the chest. The ventilatory response to hypercapnia is known for its large variability and reported responses may vary from 2.0 to 4.7 L/min/mmHg [3,17]. Although a correction by FVC will lead to less variability (reported values vary from 0.42 to 0.94 FVC/min/mmHg [3]), measuring the respiratory drive in patients affected by ILD using ventilatory parameters remains troublesome.

The mouth occlusion pressure generated by the inspiratory muscles at functional residual capacity (P0.1) has been proposed as an useful test to avoid these disadvantages [3,9-11]. It is independent of flow resistance and respiratory compliance and less variability is observed in various subjects [3,10]. Taken this together, we argue that ventilation and its components, may not represent an accurate output of the respiratory drive in our patients.

In daily practice, measuring P0.1 is very simple to apply and joined with a rebreathing bag, measurement of CO2 responsiveness is possible. In normal subjects, P0.1 values of 0.75-1.5 cmH2O have been described [3,10]. In addition, normal V'E/P0.1 is defined by ≥ 8 L/min/cmH2O, as evaluated by Scott and Burki [10]. The responsiveness to hypercapnia by measuring P0.1 (ΔP0.1/ΔPetCO2) in normal subjects is reported to be 0.17-0.49 cmH2O/mmHg [3,16]. This is in agreement with our results of SSc patients with a normal V'E/P0.1 (Table 2, mean ΔP0.1/ΔPetCO2 0.45 cmH2O/mmHg). Thus, in these SSc patients, the respiratory compliance and airflow resistance did not

| Table 1 Anthropometric and pulmonary function data of 73 SSc patients classified by V'E/P0.1 ≥ 8 l/min/cmH2O [10] |
|---------------------------------------------------------------|
| Age (yrs) | 54.4 (11.8) | 50.9 (14.4) | 0.25 |
| Female sex (%) | 26 (93) | 37 (82) | 0.11 |
| Height (cm) | 164 (7.2) | 171 (8.7) | 0.002 |
| Weight (kg) | 67.1 (15.3) | 69.8 (12.8) | 0.43 |
| BMI (cm/kg2) | 24.8 (5.4) | 23.9 (3.7) | 0.48 |
| lcSSc subtype (%) | 10 (36) | 34 (76) | 0.02 |
| PaO2 (kPa) | 10.4 (0.36) | 10.6 (0.29) | 0.58 |
| PaCO2 (kPa) | 5.31 (0.41) | 5.18 (0.43) | 0.25 |
| FVC (% pred) | 92.1 (19.9) | 111.1 (19.7) | 0.001 |
| DLCOc SB (% pred) | 57.7 (15.8) | 70.7 (15.1) | 0.001 |
| TLC-He (% pred) | 81.5 (16.6) | 95.4 (13.5) | <0.001 |
| FRC/TLC (%) | 53 (17) | 56 (7) | 0.23 |

*P value expressed for student T-test.
PaO2 (partial arterial oxygen pressure, kPa).
PaCO2 (partial arterial carbon dioxide pressure, kPa).
FVC (forced vital capacity, % pred).
DLCOc SB (diffusion capacity for carbon monoxide single breath, % pred).
TLC-He (total lung capacity, helium-dilution, % pred).
FRC/TLC (ratio of functional residual capacity and TLC, %).

| Table 2 Indices of MOP, CO2 rebreathing and the UCSD dyspnea score [18] of 73 SSc patients |
|---------------------------------------------------------------|
| V'E/P0.1 < 8 l/min/cmH2O N = 28 | V'E/P0.1 ≥ 8 l/min/cmH2O N = 45 | P value* |
|----------------------------------|----------------------------------|----------|
| UCSD SOBQ | 13 (3.5) | 22 (2.7) | <0.001 |
| P0.1 | 1.60 (0.57) | 1.10 (0.31) | <0.001 |
| V'E | 8.7 (2.3) | 11.6 (3.5) | <0.001 |
| V'E/P0.1 | 5.68 (1.24) | 10.83 (2.46) | <0.001 |
| ΔV'E/ΔPetCO2 | 2.31 (2.0) | 2.49 (1.76) | 0.71 |
| (ΔV'E/FVC)/ΔPetCO2 | 0.93 (0.72) | 0.57 (0.51) | 0.07 |
| ΔP0.1/ΔPetCO2 | 0.75 (0.42) | 0.45 (0.19) | 0.01 |

*P value expressed for student T-test.
UCSD SOBQ (shortness of breath questionnaire; score range 0–120).
P0.1 (mouth occlusion pressure at 0.1 second; cmH2O).
V'E (minute ventilation; L/min).
V'E/P0.1 (central inspiratory neuromuscular respiratory drive; L/min/cmH2O).
ΔV'E/ΔPetCO2 (hyperoxic ventilatory response to hypercapnia; L/min/mmHg).
(ΔV'E/FVC)/ΔPetCO2 (hyperoxic ventilatory response to hypercapnia, corrected for FVC; FVC/min/mmHg).
ΔP0.1/ΔPetCO2 (slope of occlusion pressure to hypercapnia; cmH2O/mmHg).
minute ventilation and during CO2 rebreathing in patients. Furthermore, our data of mouth occlusion pressures during resting capnia and is therefore considered to be normal. Further, affect occlusion pressures or the responsiveness to hypercapnia and is therefore considered to be normal. Furthermore, our data of mouth occlusion pressures during resting minute ventilation and during CO2 rebreathing in patients with normal V'E/P0.1 are consistent with those of others [3,7,10,21]. However, in the present study no significant difference was seen in ΔV'E/ΔPetCO2 between the groups as classified by V'E/P0.1 (Table 2). Since there was a significant difference present between these groups using mouth occlusion pressures, minute ventilation may not represent the neuromuscular drive adequately in SSc patients with an increased respiratory impedance.

Figure 1 Correlation between the UCSD dyspnea score [18] and V'E/P0.1 in 73 prospectively screened SSc patients. Vertical line set at V'E/P0.1 = 8 L/min/cmH2O. Horizontal line set at UCSD 8.5.

Although our reported values of the respiratory drive, as measured by P0.1, were approximately similar, differences from those previously reported by Walterspacher et al. are present [21]. Potential reasons may include the differences in degree of restrictive lung function as measured by FVC % predicted. Our SSc patients with an abnormal V'E/P0.1 had mildly reduced FVC% predicted and may have preserved inspiratory muscle function. Furthermore, our SSc patients did not avoid activities provoking dyspnea resulting into deconditioning and muscle wasting. Secondly, they did not use immunosuppressive agents affecting respiratory muscle function (prednisone). Finally, polyneuropathy, which may cause an impaired respiratory muscle function, was not likely in our patients. Therefore, respiratory drive was considered to be appropriate in our SSc population.

In our study, patients with a low V'E/P0.1 had an increased responsiveness to hypercapnia which suggests an increased central respiratory drive (Table 2). This group was characterized by fewer limited SSc patients, a lower forced vital capacity, more impaired gas transfer and a lower lung volume (Table 1). Importantly, the majority of these patients had evidence of interstitial lung disease on their HRCT and some patients had an elevated tricuspid insufficiency gradient (data not shown). The disease duration did not differ between these groups. The difference in V'E/P0.1 between the groups are related to SSc disease severity and therefore influence the impedance of the respiratory system. Consequently, differences in V'E/P0.1 were observed.

Similar results are reported by Gorini and coworkers in normocapnic ILD patients without SSc [7]. This contrasts to the concept of gradual down-regulation in central respiratory sensitivity for carbon dioxide in scleroderma patients [4]. DiMarco and coworkers concluded that in patients with ILD, non-chemical, and presumably neural, mechanisms, both increase respiratory drive and alter the breathing pattern [22].

Several factors may influence the central sensitivity to CO2 as measured by the ventilatory response to hypercapnia, such as the hormonal status, sex, age, use of sedative agents and caffeine [8,17]. However, these factors will generally not result into an abnormal V'E/P0.1 since the compliance of the respiratory system or airway resistance is not affected.

Some considerations may apply to our study. First, we evaluated MOP and CO2 rebreathing in patients with systemic sclerosis. We used a dataset of normal values for normal resting minute ventilation as a function of occlusion pressures (V'E/P0.1) [10]. As reported by others a value higher than 8 L/min/cmH2O independent of age or sex, identifies subjects with normal PFTs and therefore provides a reliable index of respiratory drive [3,10]. Consequently, we restricted our measurements in a patient group, only classified by V'E/P0.1. Our study contained 73 patients, which was similar to previous studies evaluating mouth occlusion pressures [3,10], and considered to be sufficient for group difference statistics. Despite the relatively mild range in low dyspnea scores (range 0–21; Figure 1), a significant difference in V'E/P0.1 and ΔP0.1/ΔPetCO2 was present (Table 2), indicating the sensitivity of the mouth occlusion pressure test. Furthermore, assessing V'E/P0.1 to an additional load such as exercise may have increased this difference since airflow resistance will increase and consequently the impedance of the respiratory system.

Secondly, we did not measure the sensation of dyspnea, as assessed at rest by the UCSD questionnaire, during CO2 rebreathing. To evaluate the relationship between the intensity of dyspnea and respiratory chemosensitivity may have strengthen our results, however this questionnaire was not designed to be administered during a rebreathing or exercise test.

Conclusions

In summary, the results of the present study show that patients with systemic sclerosis display a substantial variability in the ventilatory response to hypercapnia. In contrast, mouth occlusion pressures, independent of
respiratory compliance or airflow resistance, provide an accurate outcome parameter in combination with minute ventilation as an initial evaluation for mild dyspnea. They better relate to the magnitude of patient reported dyspnea than traditional lung function parameters such as FVC or DLCO% predicted. Furthermore, in our SSC patients with an abnormal V'/E/P0.1, an increased respiratory drive to hypercapnia was present. Since dyspnea is one of the most frequently reported symptoms at first consultation in SSC, an easy test to discriminate between normal or abnormal respiratory involvement in SSC patients. Therefore, we suggest that an abnormal V'/E/P0.1 in combination with reported dyspnea indicates further assessment of respiratory involvement in SSC patients.

Competing interests
The authors declare they have no competing interests.

Authors’ contributions
MKN, WBGJH, AJMS and JS designed the study. MKN, WBGJH, AJMS, JS all contributed to the clinical work for the study. MKN, WBGJH and JS analyzed the data and wrote the manuscript. All authors read and approved the final manuscript.

Acknowledgments
The authors like to thank the study participants and Berend Stoel for assisting in the medical statistics.

Funding
The authors declare that there is no funding for the present manuscript.

Author details
1Department of Pulmonology (C3), Leiden University Medical Center, PO Box 9600, Leiden 2300RC, the Netherlands. 2Rheumatology, Leiden University Medical Center, Leiden, the Netherlands.

Received: 20 July 2013 Accepted: 28 March 2014 Published: 4 April 2014

References
1. Black CM, Stephen C: Systemic Sclerosis (Scleroderma) And Related Disorders. In Oxford Textbook of Rheumatology. Edited by MadisonPJ IDA, Woop GDN. Oxford: Oxford University Press; 1993:771.
2. LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA Jr, Rowell N, Wollheim F: Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988, 15:202–205.
3. Whiteaw WA, Derenne JP, Milic-Emili J: Occlusion pressure as a measure of respiratory center output in conscious man. Respir Physiol 1975, 23:181–199.
4. Nagel TT, Du Bois RM: Non-invasive ventilation in hypercapnic respiratory failure secondary to sclerodermic chest wall restriction. Respir Med 1998, 92:1170–1172.
5. Pugazhenthi M, Cooper D, Ratnakant BS, Postlethwaite A, Carbone L: Hypercapnic respiratory failure in systemic sclerosis. J Clin Rheumatol 2003, 9:43–46.
6. Cherniack RM, Snidal DP: The effect of obstruction to breathing on the ventilatory response to CO2. J Clin Invest 1956, 35:1286–1290.
7. Gorini M, Spinelli A, Ginanni R, Duranti R, Gigliotti F, Arcangeli P, Scano G: Neural respiratory drive and neuromuscular coupling with CO2 rebreathing in patients with chronic intestinal lung disease. Chest 1989, 96:624–630.
8. Patrick J: The influence of age, sex, body size and lung size on the control and pattern of breathing during CO2 inhalation in Caucasians. Respir Physiol 1972, 16:337–350.
9. Milic-Emili J, Whiteaw WA, Derenne JP: Occlusion pressure, a simple measure of the respiratory center output. N Engl J Med 1975, 293:1029–1031.
10. Scott GC, Burki NK: The relationship between resting ventilation to mouth occlusion pressure. An index of resting respiratory function. Chest 1990, 98:900–906.
11. Calverley PMA: Ventilatory Control And Dyspnea. In Chronic Obstructive Pulmonary Disease. Edited by Calverley PMA, Pride NB. London: Chapman and Hall, 1995:205–242.
12. ATS Board of Directors: ATS/ERS Statement on respiratory muscle testing. Am J Respir Crit Care Med 2002, 166:518–624.
13. Jordan C: Automatic method for measuring mouth occlusion pressure response to carbon dioxide inhalation. Med Biol Eng Comput 1981, 19:79–286.
14. MacIntyre N: Standardisation of the single-breath determination of carbon monoxide uptake in the lung. Eur Respir J 2005, 26:720–735.
15. Miller MR: Standardisation of spirometry. Eur Respir J 2005, 26:319–338.
16. Montes de Oca M, Celi BR: Mouth occlusion pressure, CO2 response and hypercapnia in severe obstructive pulmonary disease. Eur Respir J 1998, 12:666–671.
17. Read DJC: A clinical method for assessing ventilatory response to carbon dioxide, Aust Ann Med 1967, 16:30–32.
18. Retjens GJWM, Kuipers H, Kester ADM, Keizer HA: Validation of a computerized metabolic measurement system (Oxycon-Pro) during low and high intensity exercise. Int J Sports Med 2001, 22:291–294.
19. Eakin EG, Resnikoff PM, Prewitt LM, Ries AL, Kaplan RM: Validation of a new dyspnea measure. The UCSD shortness of breath questionnaire. Chest 1998, 113:609–624.
20. Nishino T: Dyspnnea: underlying mechanisms and treatment. Br J Anaesth 2011, 106:463–474.
21. Walterspacher S, Schlager D, Walker DJ, Muller-Querheim J, Windisch W, Kabitz H: Respiratory muscle function in interstitial lung disease. Eur Respir J 2013, 42:211–219.
22. DiMarco AF, Kelsen SG, Cherniack NS, Gothe B: Occlusion pressure and breathing pattern in patients with interstitial lung disease. Am Rev Respir Dis 1983, 127:425–430.

Cite this article as: Ninaber et al: Increased respiratory drive relates to severity of dyspnea in systemic sclerosis. BMC Pulmonary Medicine 2014 14:57

Submit your next manuscript to BioMed Central
and take full advantage of:
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution

Submit your manuscript at www.biomedcentral.com/submit